Regulation and proinflammatory properties of the chemotactic protein CP-10  by Geczy, Carolyn
ELSEVIER Biochimica et Biophysica Acta 1313 (1996) 246-252 
Biochi~ic~a 
et Biophysica A~ta 
Regulation and proinflammatory properties of the chemotactic protein, 
CP-10 
Carolyn Geczy * 
The Heart Research Institute, 145 Missenden Road, Camperdown, NSW 2050, Australia 
Received 17 June 1996; accepted 19 June 1996 
Keywords: S100 protein; Inflammation; Chemotaxis; Macrophage; Endothelial cell; Cytokine 
1. Introduction 2. Structure-function studies 
Leukocyte recruitment is a central event in the patho- 
genesis of inflammation and recent studies indicate a 
variety of factors and chemokines which may be responsi- 
ble for the temporal changes during the response and 
determine the cellular composition of the infiltrate [1,2]. 
We have a long-standing interest in mechanisms involved 
in accumulation of leukocytes at sites of antigen challenge, 
particularly in delayed type hypersensitivity (DTH) re- 
sponses and showed earlier that supernatants of activated 
murine spleen cells contained a protein of heterogeneous 
size that caused similar temporal histopathological changes 
to those typical of antigen-provoked DTH reactions [3]. 
The purified factor had an apparent molecular mass of 
10300 Da and was named chemotactic protein, 10 kDa 
(CP-10). The partial amino acid sequence indicated that 
the protein was a member of the S100 family [4]. 
The cDNA sequence of CP-10 contains an ORF of 267 
bp encoding 88 amino acids of calculated mol wt. 10 163 
[5]. The protein contains one putative N-glycosylation site 
but there is no evidence, by mass spectral analysis, of 
glycosylation of the native protein from a variety of 
sources. CP-10 cDNA expressed in E. coli [6] or in a 
mammalian transient ransfection system [5] encodes a 
chemotactic protein. Pure E. coli-derived recombinant CP- 
10 has activity equivalent o the native protein and is 
chemotactic to human and murine leukocytes. 
* Corresponding author. Present address: School of Pathology, Faculty 
of Medicine, The University of New South Wales, Kensington, NSW 
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Murine CP-10 has highest amino acid sequence identity 
(59%) with the human protein of myeloid origin, 
macrophage migration inhibition-related protein, MRP8, 
also known as calgranulin A or S100A8. Pure MRP8 
alone, or complexed with the related S 100 protein MRP14, 
does not affect the migration of human monocytes [7] and 
is not active in chemotaxis assays performed in parallel 
with CP-10. The cDNA sequence of murine CP-10 was 
identical to that of murine MRP8 reported by Lagasse [8] 
which was derived from a single clone obtained by screen- 
ing a murine spleen cDNA library with a polyclonal 
antibody to human MRP8 [9]. The functional relationship 
of the human and murine proteins is unresolved. Mass 
spectral analysis indicate that neither native human MRP8 
nor native murine CP-10 contain post-translational modifi- 
cations (M. Raftery, unpublished observations) which may 
account for these differences. Their relatively low level of 
amino acid identity is atypical of the highly conserved 
nature of other proteins in the S100 family [10]. Both 
proteins have been associated with inflammation [7,11,12]. 
CP-10 was purified as a monomer [4], the predominant 
form in neutrophils and activated macrophages. Human 
MRP8 is usually complexed with a related S100 protein, 
MRP14 (calgranulin B, S 100A9) and the complex is known 
as the L1 antigen [13,14]. 
The calcium binding domains of murine CP-10 and 
human MRP8 share 59% amino acid identity but there is 
only weak homology (21%) within the 'hinge' region and 
part of the neighbouring a-helix joining the two calcium 
binding domains (CP-1042_55). The chemotactic potencies 
of peptides synthesised according to the amino acid se- 
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quences of equivalent regions of CP-10 and MRP8 were 
compared and although CP-1042-55 was some hundred-fold 
less potent than the native protein, MRP843_56 was inac- 
tive on human and murine cells, possibly because of 
predicted differences in secondary structure [5]. Although 
the full length protein allowed maximal functional activity, 
this study confirmed the earlier prediction of Kligman and 
Hilt [10] that, because of the highly conserved structural 
organisation of the S100 proteins, divergence within the 
hinge region between different members of the family may 
determine functional characteristics. In addition, and un- 
like a number of functions of S100 proteins which appar- 
ently depend on dimer formation [10], monomeric CP-10 is 
chemotactic. 
We have confirmed the ability of CP-10 to bind Ca 2- 
(P. Alewood and C. Geczy, unpublished data), but its 
importance in regulating its function is unclear. Attempts 
to perform the chemotaxis assay in calcium-free conditions 
resulted in poor overall migration of leukocytes to a range 
of chemoattractants making data difficult to interpret. 
Computer-aided molecular modelling indicates that the 
calcium-bound and free forms of CP-10 are typical of the 
S100 class, with two well-structured helix-loop-helix mo- 
tifs. Significant differences were observed between each 
form and, in contrast o the calbindin structure, the hinge 
displayed an c~-helical configuration (M. Lackmann, B. 
Smith, P. Alewood, unpublished ata). Ca2+-binding may 
alter the conformation of the protein to allow optimal 
interaction of the hinge region with the target cell. CP-10 
binds Zn 2+ with relatively low affinity [15] but it has little 
apparent effect on its chemotactic properties. 
3. Cellular expression of CP-10 
CP-10 was originally isolated as a soluble product of 
Concanavalin A-activated routine spleen cells [4] but was 
later found as a constitutive cytoplasmic protein in neu- 
trophils from the bone matTow and in elicited neutrophils 
[6]. Although we reported that elicited murine peritoneal 
exudate macrophages express low levels of CP-10 mRNA 
and protein, this may be due to residual neutrophil contam- 
ination. CP-10 is apparently not expressed by resting or 
activated lymphocytes, by fibroblasts or by unstimulated 
endothelial cells [6] but is an activation product of 
macrophages [16] and endothelial cells (T. Yen et al., 
manuscript in preparation). The gene is markedly upregu- 
lated in a variety of macrophage populations and in mi- 
crovascular endothelial cells following activation with bac- 
terial lipopolysaccharide (LPS), indicating that CP-10 may 
contribute to leukocyte infiltration in gram-negative s psis. 
Table 1 summarises the expression of CP-10 mRNA and 
protein, determined by a sensitive ELISA assay [17] or by 
Western blotting or immunohistochemistry using a poly- 
clonal antibody with poor reactivity with mMRP14 and no 
cross reactivity with human MRP8, MRPl4 or bovine 
S100b. 
Table 1 
Cellular expression ofCP- 10 
Cell Type mRNA Protein 
bone marrow + + + + + + + 
elicited neutrophils + + + + + 
blood neutrophils ND + + + 
blood monocytes ND - 
elicited Mac - - 
LPS-activated Mac + + + + 
endothelial cells - - 
LPS-activated ndothelial cells + + + 
fibroblasts (3T3) - - 
splenic T cells - - 
EL4 thymoma - - 
RAW macrophage cell line - - 
LPS/LPS-activated RAW + + + + 
WEHI monocytoid cell line - - 
LPS/LPS activated WEHI + + + + 
Bone-marrow-derived Mac + _ 
Relative xpression of CP-10 mRNA using a eDNA riboprobe as de- 
scribed [15] and of CP-10 protein by ELISA [16], immunohistochemistry 
or Western blotting [15]. 
S100 proteins are expressed in a tissue/cell-specific 
manner and earlier reports indicate a differentiation-related 
pattern of expression of the MRP8/14  complex [18,19]. 
The two proteins are abundant in neutrophils, with low 
levels in blood monocytes, but not tissue macrophages 
whereas the complex is variably expressed in macrophages 
at sites of inflammation [9,20-22]. Our studies indicate 
that the differentiation state of monocytes/macrophages 
and endothelial cells, and the nature of the activation 
triggers, offer additional evels of control of CP-10 gene 
induction. We have no evidence for constitutive xpression 
of CP-10 in monocytes/macrophages. Induction in murine 
monocytoid (WEHI 265) and macrophage-like (RAW 264) 
cell lines occurs via an acquired response involving prim- 
ing with low doses of LPS followed by challenge with a 
higher dose [16]. Interestingly, this two-step procedure 
'tolerises' RAW cells and other macrophage populations 
resulting in the suppression of proinflammatory c tokines 
such as interleukin (IL) 1, IL6, IL8, and tumor necrosis 
factor a (TNFa) and may represent a regulatory mecha- 
nism to limit uncontrolled inflammation [23,24]. Induction 
of CP-10 under these circumstances may protect he host 
from a potential desensitising effect and contribute to the 
continued recruitment of naive (unprimed) leukocytes with 
the capacity to produce other important cytokines. Intra- 
venous injection of IL8 downregulates inflammatory re- 
sponses in the extravasculature [25]. Similarly, release of 
CP-10 into the bloodstream following initial contact with 
monocytes with low levels of LPS could promote leuko- 
cyte recruitment away from inflammatory sites and the 
necessity for a second high dose challenge may avoid 
intravascular activation. 
In contrast to the above, as little as 10 ng /ml  LPS 
directly activates CP-10 mRNA in periodate-elicited 
macrophages [16]. Recent studies indicate that thioglycol- 
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late-elicited macrophages exhibit similar responses and 
that ILl/3 and TNFce differentially upregulate the CP-10 
gene in elicited macrophages (Xu et al., in preparation). 
Elicited macrophages may be preactivated as a conse- 
quence of the recruitment process [26], so as to respond 
directly to other signals following migration from the 
blood. In contrast to RAW and WEH1 cell lines, challenge 
of LPS-primed, elicited macrophages downregulated CP-10 
mRNA expression indicating that particular macrophage 
populations exhibit 'tolerised' responses imilar to those 
described above for other major macrophage-derived 
proinflammatory c tokines. 
The high levels of CP-10 mRNA expressed in PMN in 
bone marrow declined rapidly in culture with macrophage 
colony stimulating factor (CSF-1) a response interpreted 
by Goebeler et al. [27] to be differentiation-associated. We 
believe that this is associated with PMN death as the high 
constitutive l vels of mRNA in freshly isolated bone mar- 
row cells decreased to low levels after 4 h culture with or 
without CSF-1 (Hu, unpublished data). Nevertheless, CSF- 
1-differentiated bone marrow-derived macrophages (7-10 
days) failed to respond irectly or after priming and stimu- 
lating with LPS [16] further indicating the heterogeneity of 
macrophage r sponses. 
S100 proteins lack putative signal or membrane anchor 
sequences to direct secretion via classical pathways and, 
although they are generally located intracellulafly, there is 
increasing evidence for extracellular functions, [28]. Fur- 
thermore, a growing number of cytokines and growth 
factors without signal sequences are also released by alter- 
nate mechanisms apparently independent of cell death 
[29,30]. LPS-primed and challenged RAW cells express 
cell-associated and secreted CP-10. Fig. 1 shows cellular 
CP-10 is detected 2 h after challenging LPS-primed RAW 
cells whereas it's appearance in cell-free supernatants i  
more delayed, beginning 10 h after challenge and reaching 
similar levels to those found intracellularly, by 24 h. 
Although LPS priming induced CP-10 mRNA expression, 
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Fig. 1. Expression of  CP-10 by RAW macrophage-l ike c ils after pr iming 
with 10 ng /ml  LPS for 20 h and challenge with 500 ng /ml  LPS for the 
times indicated. Cell-associated ( - • - )  or secreted ( -• - )  CP-10 was 
detected by ELISA as described [15] from samples harvested at various 
times after LPS challenge. 
Table 2 
Regulation of CP-10 mRNA by inf lammatory mediators 
Stimulant Periodate- RAW Microvascular 
elicited (Mac) endothelial 
Mac cell line cells 
LPS + - + 
LPS/LPS  $ + ,1. 
IFNT + - - 
TFNoz + - with LPS 
ILl /3 + - + 
ILl o~ + - + 
Vitamin D 3 - - - 
PMA + - - 
Ca- ionophore - - - 
Expression of  CP-10 mRNA detected with a cDNA riboprobe as de- 
scribed [15]. Induction (+) ,  no induction ( - ) ,  decreased induction ($) .  
there was little obvious protein and a minimum of 5 h 
priming prior to challenge was required for protein produc- 
tion [16]. Amounts in supernatants 10 h after LPS chal- 
lenge were within the chemotactic range and release was 
not associated with dying cells. CP-10 release was inhib- 
ited by cycloheximide suggesting an active transport pro- 
cess different from that recently described for ILII3 secre- 
tion from macrophages [31]. Western blotting confirmed 
that the majority of the CP-10 expressed by RAW cells 
was monomeric and MRP14 was not found, confirming 
Northern analysis. Periodate-elicited populations contained 
CP-10, measured immediately after harvest and possibly 
due to contaminating PMN, and priming and challenge of 
these cells with LPS markedly reduced protein levels [16]. 
Abscesses (E. coli and B. fragilis) are good models of 
localised inflammation but mechanisms of control of bac- 
terial growth are still unclear. We separated large amounts 
of CP-10 and MRP14 as covalent complexes, by affinity 
purification and this procedure substantially depleted ab- 
scess fluid of its chemotactic activity [17]. Immunohisto- 
chemistry showed CP-10 throughout the abscess after 7 
days. This was expressed in a perinuclear location in PMN 
in the abscess core and within a population of cells in the 
outer capsule in a defined region of mononuclear cells as 
well as in the extracellular spaces. Although CP-10 may 
have been partially derived from dying PMN within the 
core it was maintained at high levels over 55 days and, 
together with the evidence for its induction by LPS, 
macrophages may have been the major source in chronic 
lesions [17] and its continued production may contribute to 
sustained monocyte infiltration to sites of bacterial infec- 
tion. 
Table 2 summarises the mediators known to upregulate 
CP-10 expression in murine periodate-elicited 
macrophages, the RAW macrophage-like cell line and 
brain microvascular endothelial cells. MRP8/14 is ex- 
pressed uring terminal differentiation of myelomonocytic 
cells lines such as HL60 cells differentiated with lot,25-di- 
hydroxyvitamin D3 (Vit D3) or in THP1 monocytic 
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leukemia cells activated with PMA [19]. Vit D3 or calcium 
ionophore had no effect on CP-10 expression i  any of the 
cells tested and PMA only induced mRNA in periodate- 
elicited cells. 
Interferon-~/ is a lymphocyte-derived cytokine pivotal 
for activation of macrophages in cell-mediated immunity. 
CP-10 expression i  response to interferon-~/ is apparently 
complex, with direct activation and/or suppression de- 
pending on the macrophage, type. CP-10 may be upregu- 
lated by inflammatory mediators under a variety of circum- 
stances (eg atherosclerosis, chronic bacterial and parasitic 
infections) in which macrophages are important effector 
cells and where cell-mediated immune responses are impli- 
cated. 
Postcapillary venules are the principal sites for adhesion 
and extravasation f leukocytes in inflammation. Our ear- 
lier immunohistochemical studies indicated CP-10 accu- 
mulation around endothelial cells lining small blood ves- 
sels 3 h after subcutaneous injection of LPS, with little 
expression in infiltrating cells [32]. Recent experiments 
show that LPS and ILl, but not TNFa, directly upregulate 
CP-10 mRNA and protein in brain microvascular endothe- 
lial cells (T. Yen, in preparation). The in vivo studies may 
reflect differences in the kinetics of induction of CP-10 in 
endothelial cells and macrophages a both produce optimal 
responses after culture for approximately 20 h in vitro. The 
sensitive response to very low doses of ILl suggests that it 
may be an important mediator in a microenvironment free 
of LPS. Previous reports proposed that as myeloid cells 
migrate they secreted MRP8/14 onto the endothelium 
upon adhesion and became progressively MRP negative as 
they migrated into inflamed tissue [33]. Although this 
process may occur in cells expressing these proteins, our 
studies strongly indicate active expression of CP-10 under 
proinflammatory conditions and its induction in microvas- 
cular endothelial cells supports our proposal for CP-10's 
involvement in the vascular etention of leukocytes. 
spleen cells [15], MRP14 mRNA was not coexpressed by 
any of the macrophage populations activated with LPS [ 16] 
in vitro and its expression may be regulated by other 
mediators. In contrast, MRP14 mRNA was induced in 
brain microvascular endothelial cells but we have no evi- 
dence of heteromeric complexes with CP-10. 
Bacterial abscesses expressed mMRP14 over 55 days, 
principally as disulphide-linked heterodimers with CP-10 
[17] although the cell source of the latter is undefined. The 
human MRP8/14 complex is antimicrobial nd the princi- 
pal activity is MRP14 [34,35] which may limit bacterial 
growth by virtue of its ability to chelate zinc, an essential 
element for bacterial growth [36], but we failed to demon- 
strate antimicrobial activity using pure CP-10 and/or 
mMRP14 [17]. Human and murine MRP14 are structurally 
different; mMRP14 has several post-translational modifica- 
tions including an S-S loop between CYST9 and Cys90 and 
• • - -65~ 2+ a novel 1-methylation f His106. Both proteins oma Ln 
with higher affinity than CP10 or S100b and the Zn 2+ 
binding site/s are apparently distinct and independent of
the two Ca 2+ binding domains [15]. Human MRP14 con- 
sists of full-length and N-truncated forms, has no internal 
S-S loop, the free Cys at the N-terminus is absent in the 
truncated form, has no Me-His residues [15] and the 
penultimate Thr can be phosphorylated upon PMN activa- 
tion [20]. Whether the structural differences determine 
distinct functions for these proteins is unknown. Interest- 
ingly, the C-terminal domain of human MRP14 has se- 
quence identity with a peptide which inhibited chemotaxis 
to classical chemoattractants C5a and FMLP [37] but 
recent experiments with synthetic peptides showed no 
effect [38]. Notwithstanding, these proteins may play a role 
in leukocyte migration and activation as intracellular MRP8 
and 14 in human PMN translocate from the cytoplasm to 
the cell membrane may be involved in highly specific 
Ca2+-dependent signalling pathways and cytoskeletal 
changes provoked by classical chemottractants [31,39,40]. 
3.1. CP-IO and MRP14 are not always co-ordinately 
expressed 
Although MRPI4 is also a newly-synthesised protein 
recently isolated from supernatants of activated murine 
3.2. Functional characteristics of CP-IO 
Chemotaxis i  a primitive function of phagocytic ells 
involved in innate host responses. Recently, two distinct 
classes of chemoattractants were proposed [41], because of 
Table 3 
Comparisons of functional responses of neutrophils to chemoattractants 
fMLP,IL8,C5a CP-10 TGF-fl 1 
Chemotaxis potency + + + 
10-7 -10  -9 M 10-11-10 -13 M 10-12-10 -14 M 
Actin polymerisation + + + 
PT inhibition of CT + + + 
Intracellular Ca2 + flux + - - 
Degranulation + - - 
Induction of Mac 1 (CD1 lb /CD18)  + - - 
Shedding of L-selectin + -- -- 
Oxidative burst + - - 
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a divergence in the ability of some agents to provoke 
migration in the absence of activation. Like transforming 
growth factor /3 (TGF/3), CP-10 is more potent han the 
chemokines or complement-derived chemoattractants, with 
optimal activity for murine neutrophils (PMN) between 
10-12-10 -13 M. Table 3 compares ome properties of 
CP-10 [42] with the classical chemoattractants which stim- 
ulate directed migration and activation. TGF/3 [41] and 
CP-10 belong to the class of 'pure chemoattractants' which 
provoke actin polymerisation a d changes in cell shape but 
fail to cause degranulation or generate an oxidative burst. 
Like chemotaxis to FMLP or C5a chemotaxis to CP-10 
was mediated by a pertussis toxin sensitive G-protein-cou- 
pled pathway but the inability of CP-10 to increase levels 
of intracellular calcium suggest a mechanism similar to 
that proposed for TGF[3, which may not involve G-protein 
pathways coupled to phosphotidylinositol- r phospho- 
tidylcholine-linked phospholipases. A number of reports 
suggest hat leukocyte migration can proceed without in- 
crements of [Ca 2÷ ]i [43,44] and our studies support he 
notion of independent signal transduction pathways for 
migration and activation in leukocytes. Interestingly, the 
mechanism of action of CP-10 is apparently different from 
that required for the changes in glial cell morphology, 
cytoskeletal reorganisation and possibly growth cone mo- 
bility promoted by extracellular S 100b which causes rapid 
increases in (Ca2+)i n glial and neuronal cells [45]. 
Polymerisation of F-actin is a central event in cell 
migration and reorganization from monomeric G-actin to 
F-actin occurred after 30 s incubation with CP-10 in both 
PMN and WEHI 265 monocytoid cells [42]. Increases in 
F-actin correlated with changes in cell shape after 30-60 s 
and profound changes were observed if WEHI cells were 
incubated with CP-10 for 90 min. This effect was stronger 
than that described for TGFI3 [46] and more apparent with 
adherent cells, although the potential for costimulation by 
ligation of adhesion receptors, which causes slow and 
persistent actin polymerisation [47], has not been fully 
investigated. 
The expression and function of adhesion receptors on 
leukocytes i upregulated by the classical chemoattractants 
and in accordance with the inability of CP-10 to cause 
degranulation, CDl lb (Mac-l) was not upregulated i- 
rectly by CP-10 although CP-10 recruited-leukocytes ex-
press increased levels. Leukocyte retention in microcappi- 
laries is an important event in the initiation of inflamma- 
tion in vascular beds. This may occur through geometric 
constraints caused by increased cell size and stiffening, 
principally due to increased F-actin, particularly in pseu- 
dopodia, and to the formation of stress fibres [44,48]. Our 
studies using confocal microscopy showed that CP-10 
increased the size of WEHI cells by 3- to 10-fold and of 
PMN by 4-fold, to areas which could readily block micro- 
capillaries, and the monocytoid cells formed long finger- 
like lamellipodia with intensely-stained F-actin stress fi- 
bres. The rapid retention of PMN in pulmonary capillaries 
following administration of LPS is not dependent on 
CD 11/CD ! 8-mediated adhesion [48,49], and because ap- 
propriately activated endothelial cells express CP-10, this 
may mediate the early vascular esponse. The inability of 
CP-10 to directly initiate L-selectin shedding may be 
important in the initial binding of leukocytes to the mi- 
crovascular endothelium prior to transmigration. Increase 
deformability could contribute to ischemic events in disor- 
ders such as sepsis, post-traumatic shock and myocardial 
infarction. 
3.3. Activity of CP-IO in vivo 
The histopathological changes and the macrophage phe- 
notype recruited by CP10 are distinct from those described 
for other chemoattractants and chemokines. CP-10 and the 
hinge region peptide (CP-1042_55), elicit leukocyte recruit- 
ment in vivo. Variations in the responses at different 
injection sites have been observed and may reflect the 
composition of the microenvironments and/or peptide lo- 
calisation and clearance. Optimal concentrations (recombi- 
nant CP-10, 10 -7 M; CP-1042_55, 10 -6 M) required to 
provoke recruitment [32] are higher than for chemotaxis n
vitro and potencies are similar to those described for some 
rat chemokines in vivo [49]. Approx. 10-times more CP- 
1042_55 is required to elicit a peritoneal infiltrate than 
when injected s.c. 
Footpad injection with rCP-10 causes an intense infiltra- 
tion of PMN after 3 h which peaks after 8 h followed by a 
mixed mononuclear infiltrate more obvious after 12 h 
[5,32]. The increased expression of CD 1 lb (Macl inte- 
grin) and decreased L-selectin on elicited leukocytes en- 
hances their tight adhesion to the vasculature and promotes 
transmigration [50]. The PMN infiltrate elicited by CP-10 
were Mac-1 high and L-selectin low [32], characteristics 
similar to those of PMN elicited by classical factors such 
as FMLP and IL8 [50,51]. Similar kinetics were observed 
following intraperitoneal injection of CP-1042_55 with an 
absolute increase in monocyte/macrophage numbers of 
approximately 5-fold after 24 h [52]. Table 4 summarises 
some of the properties of CP-10-elicited murine 
Table 4 
Characteristics of CP- 10-elicited macrophages 
Enlarged size, increased vesicles, endoplasmic reticulum, pseudopodia 
F4/80 antigen low 
CD1 lb/CD18 high 
$ Scavenger receptor 
~" TNFa production 
J, Nitric oxide production 
"r AcLDL loading ~ foam cells 
$ Phagocytosis 
Characteristics of monocytes recruited over 16-36 h following i.p. injec- 
tion of mice with CP-1042_55. 
Expression higher (~') or lower (,1,) as described (Lau) than on 
macrophages from mice injected with diluent control. 
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macrophages. The observed changes were not all due to 
the direct effect of CP-10 oil these cells and secondary, as 
yet uncharacterised mediators, probably contribute to its in 
vivo effects. In contrast to resident peritoneal macrophages 
which express high levels of the macrophage-specific anti- 
gen F4 /80 ,  the low level on CP-10-elicited macrophages 
suggests activation and these cells are larger and more 
vacuolated than resident macrophages [52]. Apart from the 
coordinated upregulation of CDl lb /CD18,  LFA-1 and 
VLA-4 integrins were not altered confirming these as 
newly-recruited cells [53]. Moreover, levels of scavenger 
receptor were markedly higher than those expressed on 
macrophages elicited by other agents including thioglycol- 
late and CSF1 and CP-10-elicited macrophages accumu- 
lated significantly greater levels of cholesterol esters, a 
reflection of lipid loading [54], in response to acetylated 
low density lipoprotein (AcLDL) in vitro and in vivo. 
Scavenger receptor activity increases with macrophage 
maturation and differentiation and is thought o contribute 
to potential foam cell dew,qopment [55,56]. Furthermore, 
CP-10-elicited macrophages express high levels of Fc re- 
ceptors and are strongly phagocytic (Lau et al., in prepara- 
tion), additional parameters indicative of an activated phe- 
notype. Ours was the first demonstration of macrophage 
foam cell formation in an experimental system in vivo and 
the cholesterol ester profiles of extracted lipids were simi- 
lar to those of cells freshly isolated from human athero- 
sclerotic plaque [52]. 
The data presented strongly implicate CP-10's involve- 
ment in leukocyte recruitment and retention within the 
microvasculature in inflammation. Upregulation of CP-10 
by LPS and IL l  in macrophages and endothelial cells 
suggest its importance in non-specific and immune-media- 
ted conditions and it may provide an important host re- 
sponse in gram-negative bacterial infection. In addition to 
its potent chemotactic activity, CP-10 may also contribute 
to the inflammatory response by its capacity to modulate 
the activation state of recruited leukocytes. CP-10-elicited 
macrophages are activated and can form foam cells, 
strongly implicating its involvement in atherogenesis, and 
these cells may have additional important effector func- 
tions. CP-10 may act with other chemokines, to contribute 
to amplification mechanisms required for the sustained 
recruitment of monocytes in chronic inflammatory condi- 
tions. 
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